IgPro
ApprovedBiologic
CSL BehringIgPro is one of 44 biologic programs targeting Immunodeficiency. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Repatha
AmgenPhase 3
Farxiga
AstraZenecaPhase 3
Emtriva
GileadPhase 3
Edurant Ped
WWim Janssens
Phase 3
Vemlidy
GileadPhase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Livalo
MMedicure
Phase 3
Immunoglobulin
SanofiPhase 3
Atripla
GileadPhase 3
PPSV23
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IgPro. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company